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Abstract
Background Frailty is a state of increased vulnerability to
poor resolution of homeostasis after a stressor event, which
increases the risk of adverse outcomes including falls,
disability and death. The underlying pathophysiological
pathways of frailty are not known but the hypothalamic–
pituitary–adrenal axis and heightened chronic systemic
inflammation appear to be major contributors.
Methods We used the English Longitudinal Study of
Ageing dataset of 3160 individuals over the age of 50 and
assessed their frailty status according to the Fried-criteria.
We selected single nucleotide polymorphisms in genes
involved in the steroid hormone or inflammatory pathways
and performed linear association analysis using age and sex
as covariates. To support the biological plausibility of any
genetic associations, we selected biomarker levels for
further analyses to act as potential endophenotypes of our
chosen genetic loci.
Results The strongest association with frailty was
observed in the Tumor Necrosis Factor (TNF) (rs1800629,
P = 0.001198, b = 0.0894) and the Protein Tyrosine
Phosphatase, Receptor type, J (PTPRJ) (rs1566729,
P = 0.001372, b = 0.09397) genes. Rs1800629 was sig-
nificantly associated with decreased levels of high-density
lipoprotein (HDL) (P = 0.00949) and cholesterol levels
(P = 0.00315), whereas rs1566729 was associated with
increased levels of HDL (P = 0.01943). After correcting
for multiple testing none of the associations remained
significant.
Conclusions We provide potential evidence for the
involvement of a multifunctional proinflammatory cyto-
kine gene (TNF) in the frailty phenotype. The implication
of this gene is further supported by association with the
endophenotype biomarker results.
Keywords Frailty  SNP  TNF  Biomarker
Introduction
Frailty refers a state of increased vulnerability to poor
resolution of homeostasis after a stressor event, which
increases the risk of adverse outcomes, including falls,
delirium and disability [1]. The mechanistic pathophysio-
logical pathways of frailty are not known, but there is
evidence for the involvement of steroid hormones and the
immune system [2, 3]. During ageing, physiological
decline occurs in steroid hormone levels, as observed in
males where free testosterone declines at the rate of 1 %
per year [4]. Similarly, in females cycling estradiol pro-
duction is replaced by very low, constant, estradiol levels
after the age of about 50 [5]. In both sexes, dehy-
droepiandrosterone (DHEA) and its sulphated derivate
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(DHEAS) levels gradually decline in later life due to the
decreased activity of adrenal glands [6]. These hormones
are known to effect changes in proinflammatory cytokine
levels, for example, testosterone was shown to suppress
interleukin-6 (IL-6) mRNA levels in osteoblastic cell line
[7] and reduce the expression and secretion of tumor
necrosis factor (TNF) in macrophages [8]. Estradiol in
human bone-derived cells inhibits TNF-induced IL-6 pro-
duction [9]. Finally, DHEA concentration has been shown
to inhibit IL-6 secretion from peripheral blood mononu-
clear cells [10]. The increased levels of proinflammatory
cytokines (IL-1, IL-6 and TNF) and acute-phase proteins,
such as C-reactive protein (CRP), results in a chronic, low-
grade systemic inflammatory state of the ageing immune
system, termed ‘‘inflamm-ageing’’. This chronic inflam-
mation leads to long-term tissue damage and is detrimental
for longevity [11]. Increased levels of CRP and IL-6 have
been associated with increased mortality in the elderly [12,
13]. Studies have shown a large body of evidence sug-
gestive of a heightened inflammatory state in frail older
individuals, as marked by increase of these inflammatory
markers compared with levels observed in robust older
controls [14–16].
There have been only a few studies on the genetic
determinants of frailty and those that have been conducted
have somewhat conflicting results. A candidate gene study
found that two single nucleotide polymorphs (SNP) of the
IL-6 gene were weakly associated with frailty but not with
serum IL-6 levels [17], whilst another showed that a SNP
in the CRP gene (rs1205) is associated with frailty scores,
albeit counter intuitively with presence of frailty related to
lower levels of CRP [18]. The largest study so far (in terms
of number of SNPs investigated) has found weak associa-
tions between frailty and genetic variants of genes involved
in pathways related to apoptosis and metabolism of amino
acids in a sample of elderly women [19]. However, these
results did not survive correction for multiple testing.
In this study, we conducted a candidate gene association
study using a standardized frailty phenotype [20] in 3160
community dwelling individuals over the age of 50 in the
English Longitudinal Study of Ageing (ELSA) cohort. We
selected genes involved in the steroid hormone biosyn-
thesis and inflammation pathways, as evidence in the lit-
erature indicates their possible involvement in frailty
pathophysiology (for example, DHEAS [21], IL-6, TNF
and C-reactive protein [14]). We also selected genetic
variants of key genes of the steroid hormone and inflam-
matory pathways, such as HSD11B1, SULT1E1, SULT2A1,
IL1B and IFNG. We hypothesized that SNPs within these
genes, especially those ones which have been shown to
affect the expression of their genes such as rs1800795 for
IL6 [22] and rs1800629 for TNF [23] or have shown
associations with metabolite levels such as rs2547231 and
rs182420 for SULT2A1 [24], will show significant associ-
ation to frailty phenotype.
To support the biological plausibility of any genetic
association with the frailty phenotype, we also conducted
association analyses with selected biomarkers that act as
potential endophenotypes for our chosen genetic loci: high-
sensitivity C-reactive protein (hsCRP) as inflammatory
marker, high-density lipoprotein (HDL), total cholesterol
and DHEAS as markers for steroid metabolism.
Materials and methods
Participants
The analyses are performed on a sample of 3160 partici-
pants drawn from Wave 2 (2004) and Wave 4 (2008) of the
English Longitudinal Study of Ageing (ELSA). Detailed
description of ELSA can be found elsewhere [25], (http://
www.ifs.org.uk/ELSA). Briefly ELSA is prospective
cohort study representative of older men and women living
in England who originally participated in the Health Sur-
vey for England in 1998, 1999 or 2001 (http://www.natcen.
ac.uk/series/health-survey-for-england). The participants
have been participated biannually in a computer-assisted
personal interview (Core dataset) and every 4 years for a
separate nurse assessment (Nurse dataset), carried out
shortly after the interview. During the nurse assessment
participants gave blood for genetic and biomarker analysis.
Genetic and biomarker data
Genotype data of 620 Single Nucleotide Polymorphisms
(SNP) for 3160 participants were obtained from a publicly
available ELSA DNA Repository (EDNAR).
Genotyping was performed by Illumina (San Diego,
CA) as part of a 1536 Goldengate custom SNP panel using
high-throughput BeadArrayTM technology.
For the comparative endophenotype analysis, biomarker
data were drawn from both the Wave 2 (2004) and Wave 4
(2008) Nurse dataset. We used the following analytes from
W2: blood total cholesterol (mmol/l), HDL (mmol/l), and
hsCRP (mg/l). HsCRP[10 mg/l results were excluded
from the analysis as they indicate ongoing acute-phase
response [26]. From W4, we used the DHEAS level (lmol/
l). Blood samples were analysed at the Royal Victoria
Infirmary laboratory in Newcastle upon Tyne, UK (detailed
description of blood analyses can be found in [27]).
Phenotypic measures
Frailty status assessment was based on the 5-item criteria
by Fried and colleagues [20], derived for both Wave 2 and
Aging Clin Exp Res
123
Wave 4. This is a widely used measure which determines
the condition based on specific criteria, such as uninten-
tional weight loss, exhaustion, low physical activity,
slowness and weakness. As with previous studies using
Frailty Phenotype (FP) criteria, we conducted a study
specific operationalization in ELSA, as follows. Weight
loss (item 1) was defined as present if changes in measured
weight loss between waves were equal or greater than 8 %
baseline values. Exhaustion (item 2) was recorded present
if a positive answer to both of the questions from the
Center for Epidemiological Studies depression question-
naire (CES-D) [28]: whether respondent felt everything
they did during the past week was an effort and whether
respondent could not get going much of the time during the
past week.
Low physical activity (item 3) used self-report questions
on work activity and recreational physical activity. In short,
if subject reported they did not work and performed only
mild sport activity not more than once a week, they were
considered positive for this item.
Respondent is considered positive for slowness (item 4)
if the average of the two timed 8 feet (=240 cm) walk test
falls into the slowest 20 % of population, adjusting for sex
and height.
Respondent was assessed as frail for weakness (item 5)
if the average of the 3 dominant hand grip strength (GS)
measures by handheld dynamometer falls into lowest 20 %
of the population stratified by sex and body mass index
(BMI). The latter 2 items were assessed in the whole ELSA
wave 2 and wave 4 cohorts with available data then the cut-
off points were applied for the genotyped sub-cohort.
(Detailed description of variables used for frailty assess-
ment can be found in the online Supplementary material
Appendix 1.)
For analysis purposes, we used these variables both as a
summed count of the number of frailty items present (0–5)
and as an ordinal frailty status measure (frail if they pos-
sessed 3–5 items, pre-frail if 1–2 items and robust if none).
Biomarker data were treated as continuous variables and
were normally distributed. However, hsCRP and DHEAS
data were skewed; therefore a square root transformation
was performed for genetic association analysis purposes to
normalize the distribution.
Statistical analysis
We used the Plink software for genetic association analyses
[29]. Associations between genotypes and number of
frailty items present (0–5) and between genotypes and
biomarker levels, and were tested with linear regression
using sex and age as covariates. Results of the most sig-
nificant associations were re-tested by ordered logistic
regression using frailty status as dependent variable within
the Stata12 software (Stata Corporation, http://www.stata.
com/). Stata12 was also used for demographic, phenotypic
and biomarker analysis. Linkage disequilibrium blocks in
PTPRJ gene were generated and visualized with Haplo-
View software [30]. Genetic power calculation was per-
formed by Quanto software (http://biostats.usc.edu/Quanto.
html).
Results
Demographic, phenotypic and biomarker
distributions
Tables 1 and 2 show the demographic and frailty pheno-
type results for the participants,, respectively. There were
more females than males in the sample with no significant
differences between the mean ages. There is evidence of a
relationship between sex and the FP but this did not
achieve statistical significance at the 5 % level in Wave 2
(P = 0.068) and was not significant in Wave 4
(P = 0.106) (Fischer’s exact test).
Table 3 shows the mean biomarker levels for the entire
population and for the two sexes. All the biomarker levels
were significantly different between sexes on the P\ 0.05
level.
To explore the predictive value of these biomarkers, we
conducted a Spearman’s correlation test. The analysis
revealed that all biomarkers were significantly correlated
with the number of frailty items at least on P\ 0.005 level
(HDL, Spearman’s rho = -0.054) or below the
P\ 0.0001 level (cholesterol, hsCRP and DHEAS, Sper-
man’s rho: -0.118, 0.098 and -0.143, respectively).
Table 4 shows the mean biomarker levels, according to
frailty categories (robust, pre-frail and frail).
Genetic association results
Of the available 620 SNPs, 15 were out of Hardy–Wein-
berg equilibrium (P\ 0.01), and a further 15 had a minor
allele frequency (MAF) below 5 %, so these were excluded
from the genetic association analysis, resulting in 590
SNPs used.
Table 5 shows the most significant results of the genetic
association analysis (for results for each of the 590 SNPs
see online Supplementary material Appendix 2). The SNP
which was most significantly associated with the number of
frailty items (0–5) phenotype is rs1800629 (b = 0.0894,
P = 0.001198) in the promoter region of Tumour Necrosis
Factor gene (TNF) on Chromosome 6. Four other SNPs
(rs1566729, rs1566728, rs2047812 and rs611646) were
associated below the P = 0.01 level (b values 0.09397,
0.09043, 0.08481 and -0.06407, respectively). The first
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three of these are located within the Protein Tyrosine
Phosphatase, Receptor type, J (PTPRJ) gene on chromo-
some 11. Two of these SNPs, rs1566729 and rs1566728,
are in very high linkage disequilibrium (LD) with each
other (r2 = 0.99) and rs2047812 with both of them
(r2 = 0.85) thus they probably indicate the same signal
Table 1 Demographic result of
participants
Total sample Males Females
Number of participants 3160 1466 1694
Mean age years (SE) in Wave 2 68.3 (0.10) 68.27 (0.14) 68.32 (0.14)
Mean age years (SE) in Wave 4 72.05 (0.11) 71.93 (0.17) 72.15 (0.15)
SE standard error of the mean
Table 2 Frailty status results of participants in Wave 2 and Wave 4
Frailty categories
Robust Pre-frail Frail
Mean number of items (SD) 0 item 1 item 2 items 3 items 4 items 5 items
Number (%) Number (%) Number (%) Number (%) Number (%) Number (%)
Total sample
Wave 2 0.52 (0.83) 1745 (63.55) 694 (25.27) 212 (7.72) 67 (2.44) 22 (0.80) 6 (0.22)
Wave 4 0.65 (0.91) 1148 (56.97) 546 (27.10) 225 (11.17) 66 (3.28) 28 (1.39) 2 (0.10)
Males
Wave 2 0.5 (0.78) 817 (64.03) 330 (25.86) 88 (6.90) 34 (2.66) 7 (0.55) 0 (0)
Wave 4 0.61 (0.86) 540 (58.89) 241 (26.28) 100 (10.91) 29 (3.16) 6 (0.65) 1 (0.11)
Females
Wave 2 0.54 (0.87) 928 (63.13) 364 (24.76) 124 (8.44) 33 (2.24) 15 (1.02) 6 (0.41)
Wave 4 0.69 (0.95) 608 (55.37) 305 (27.78) 125 (11.38) 37 (3.37) 22 (2.0) 1 (0.09)
SD standard deviation
Table 3 Biomarker level
results
Total sample Males Females
Cholesterol (mmol/l) (SE) 5.89 (0.022) 5.55 (0.030) 6.17 (0.030)
HDL (mmol/l) (SE) 1.52 (0.007) 1.38 (0.009) 1.64 (0.009)
hsCRP (max 10) (mg/l) (SE) 2.58 (0.040) 2.48 (0.059) 2.67 (0.056)
DHEAS (lmol/l) (SE) 1.9 (0.034) 2.38 (0.059) 1.53 (0.033)
All biomarker levels were significantly different in the sexes (two-group mean-comparison t test, P\ 0.05
level)
Analyses of hsCRP and DHEAS were done with square root-transformed values
HDL high-density lipoprotein, hsCRP high-sensitivity C-reactive protein, DHEAS dehydroepiandrosterone-
sulphate, SE standard error of the mean
Table 4 Biomarker levels according to frailty categories
Cholesterol (mmol/l) (SE) HDL (mmol/l) (SE) hsCRP (max 10) (mg/l) (SE) DHEAS (lmol/l) (SE)
Robust 5.978015 (0.029) 1.536526 (0.009) 2.385388 (0.050) 2.034286 (0.043)
Pre-frail 5.757667 (0.040) 1.502333 (0.013) 2.772649 (0.080) 1.678685 (0.060)
Frail 5.374468 (0.146) 1.451064 (0.040) 3.047945 (0.278) 1.8875 (0.263)
HDL high-density lipoprotein, hsCRP high-sensitivity C-reactive protein, DHEAS dehydroepiandrosterone-sulphate, SE standard error of the
mean
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(Fig. 1). Finally, the fourth SNP, rs611646 which appeared
to reduce the number of frailty items (b = -0.06407,
P = 0.003904), is an intron variant within the Ataxia
Telangiectasia Mutated (ATM) gene on chromosome 11.
None of these results survives the Bonferroni-correction
(P\ 8.474E–05 for 590 tests).
Retesting the nominally significant results (P\ 0.05) of
the genetic association analysis with ordered logistic
regression using frailty status (robust, pre-frail and frail)
phenotype confirmed the previous results. The most sig-
nificantly associated variant remained rs1800629 of TNF
(coefficient = 0.2346, P = 0.001). Of the PTPRJ genetic
variants, the same three SNPs were significantly associated
with this phenotype below the P = 0.01 threshold
(rs2047812, coefficient = 0.2095, P = 0.004; rs1566729,
coefficient = 0.2088, P = 0.006 and rs1566728, coeffi-
cient = 0.1995, P = 0.008). Finally, another SNP reached
the P = 0.01 significance level, rs4646316 (coeffi-
cient = 0.1695, P = 0.01) an intronic variant within the
Catechol-O-methyltransferase (COMT) gene on chromo-
some 22.
To provide support for biological plausibility for genetic
findings, we selected steroid hormone biosynthesis and
inflammatory pathway-related biomarkers as endopheno-
types and examined if any of the SNPs were significantly
associated with their levels.
TNF SNP rs1800629 was significantly associated with
decreased cholesterol level (b = -0.11, P = 0.003151)
and decreased HDL level (b = -0.03022, P = 0.009489).
Of the 3 PTPRJ SNPs each was significantly associated
with increased HDL levels (b values 0.02898–0.03593,
P values 0.002294–0.01943), and at least on a suggestive
level with increased square root levels of DHEAS (b val-
ues 0.03404–0.03505, P values 0.0527–0.07158). Finally,
rs611646 or rs4646316 did not have an effect on any of the
biomarker levels.
Finally, we included HDL, cholesterol and hsCRP levels
separately in a multivariate model to test if adding these
biomarker levels attenuates the association between SNPs
and frailty status. Including hsCRP in the model reduced
the coefficient to 0.1776 for rs1566728 and to 0.1898 for
rs2047812, whereas cholesterol and HDL in the model
affected the coefficient for rs611646 (-0.118 and -0.116,
respectively) (Table 6).
Discussion
In this study, we investigated the association between
genes involved in steroid hormone metabolism and
inflammatory pathways and the frailty phenotype. Our
results show evidence of the involvement of TNF, PPRJ,
ATM and COMT genes.T
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Our most significant genetic finding is with the TNF
locus on chromosome 6. The TNF gene encodes a proin-
flammatory cytokine, mainly secreted by macrophages.
This cytokine is involved in the regulation of a wide
spectrum of biological processes including cell prolifera-
tion, differentiation, apoptosis, lipid metabolism, and
coagulation and has been implicated in a variety of dis-
eases, such as autoimmune diseases, insulin resistance, and
cancer [31]. The most significant SNP, rs1800629 is
located in the promoter region of the TNF gene causing a
G[A transition. Functional studies suggest that the rare A
allele is a much more powerful transcriptional activator
than the common G allele [23]. In our study, the rare A
allele was significantly associated with possession of
increasing numbers of frailty items and becoming frail.
This agrees with the observations of elevated TNF levels in
frail individuals [15]. This SNP was significantly associ-
ated with decreased HDL and cholesterol levels as well in
our study. Relationships between TNF and blood lipid
levels have been investigated before. During septic shock
Fig. 1 Linkage disequilibrium (LD) blocks within the PTPRJ gene. Rs2047812, rs1566729 and rs1566728 are in strong correlation with each
other (R2 C 0.85), indicating that the observed associations are possibly originated from the same signal
Table 6 Results of the multivariate model
SNP Cholesterol levels in the model HDL levels in the model Square root hsCRP levels in the model
Coefficient P Coefficient P Coefficient P
Rs1800629 0.22144 0.002 0.229437 0.001 0.238789 0.002
Rs1566729 0.213732 0.005 0.219683 0.004 0.185953 0.021
Rs1566728 0.204545 0.007 0.210509 0.006 0.177571 0.028
Rs2047812 0.214303 0.003 0.222936 0.002 0.189815 0.013
Rs611646 -0.117873 0.043 -0.115613 0.047 -0.135985 0.027
Rs4646316 0.180721 0.006 0.177258 0.007 0.190133 0.006
HDL high-density lipoprotein, hsCRP high-sensitivity C-reactive protein
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increased TNF levels were found to be accompanied by a
significant decline in total serum cholesterol [32], whilst
TNF inhibitor treatment was associated with increased
levels of HDL and total cholesterol in rheumatoid arthritis
patients [33]. Studies of elderly participants found associ-
ation between lower blood lipid levels and survival. For
example, a 2-year follow-up study of very old and frail
individuals has found that HDL cholesterol levels were
significantly lower among those who died compared with
survivors [34], whilst in another 3-year follow-up study
subjects with low total cholesterol levels were at a higher
risk of dying [35]. Finally, in a genome-wide association
(GWA) study of over 100,000 individuals of European
ancestry rs1800629 A allele was associated with lower
cholesterol (P = 6.81E-09) and triglyceride
(P = 7.90E-09) levels [36]. Despite these findings, it is
possible that the frailty increasing and cholesterol and
HDL-level decreasing effects of TNF are manifested
through different pathways.
The role of the immune system in FP was not corrob-
orated by other genes, such as CRP, IL6 or IL6R in our
study. It may indicate that the effect of TNF manifests
though other pathways rather than the inflammatory, such
as apoptosis.
Our second most significant genetic association hit was
with SNP rs1566729 which lies within the PTPRJ gene.
PTPRJ is a member of the protein tyrosine phosphatase
(PTP) family. PTPs are known to be signalling molecules
that regulate a variety of cellular processes, including cell
growth, differentiation, mitotic cycle and cancer-associated
signalling processes. PTPRJ has been implicated in breast,
colon, lung and thyroid cancers [37], and it is expressed by all
resting leukocytes and upregulated following in vitro stim-
ulation, thus it appears to be a T cell activating molecule [38].
A recent study suggests a possible connection between TNF
and PTPRJ. In a mouse melanoma model treatment with
TNF yielded the downregulation of PTPRJ [39]. The 3
PTPRJ SNPs were investigated by Teslovich and colleagues
[36] who reported an increase in HDL levels (P values range
between 1.77E-08: rs1566729 to 2.71E-08: rs1566728), as
we did, but this contradicts the literature showing a negative
association with frailty that we have just described [34]. A
further contradiction is that these SNPs appear to be asso-
ciated with increased DHEAS levels, which is thought to be
protective against frailty [40]. A possible interpretation of
this counter-intuitive finding may be that an effect of PTPRJ
antagonises the HDL, DHEAS level-increasing effects and
increases frailty.
The third gene below the 0.01 significance threshold is
ATM. ATM protein is a high-molecular-weight PI3K-
family kinase. It plays many important cytoplasmic roles
where it phosphorylates hundreds of protein substrates that
activate and coordinate cell-signalling pathways involved
in cell-cycle checkpoints, nuclear localization, gene tran-
scription and expression, the response to oxidative stress,
apoptosis and nonsense-mediated decay, among others
[41]. With this wide-range of functions in the cell, this gene
and its protein product are plausible candidates for frailty.
Our top SNP within this gene, rs611646 has been associ-
ated with breast cancer in interaction with BRCA1 in a
study of Chinese Han subjects [42] indicating its possible
functionality.
The ordered logistic regression showed the possible role
of a fourth gene, COMT. The protein product of this gene
catalyses the transfer of a methyl group to catecholamines,
including neurotransmitters dopamine, epinephrine and
norepinephrine, but it also acts on oestrogen, a member of
the steroid biosynthesis pathway [43]. Rs4646316 within
this gene has been shown to be associated with
schizophrenia [44] but not with any biomarker level in our
study, making this result difficult to interpret.
Including the biomarkers into the model only slightly
attenuated the relationship between frailty status and the
SNPs in PTPRJ and ATM genes. It may indicate that the
relationship between these variables is not a direct mech-
anistic one or that biomarker levels and SNP variants are
independently associated to frailty.
The measured biomarkers were all significant predictors
for the number of frailty items possessed, but their indi-
vidual effects were small. This is in agreement with the
genetic findings which indicate the involvement of several
pathways, each with limited effects.
This study has a number of limitations. First, only a
proportion of the ELSA sample were genotyped and the
prevalence of frailty in this group was slightly lower than
in the full sample, thus it may not be representative for the
whole United Kingdom population of older adults. Second,
the frailty phenotype is constructed using study specific
items from the extensive ELSA public archive, although as
in many published studies in we used an approach based on
the method published by Fried and colleagues [20]. Finally,
the analysed biomarkers, genes and genotypic variants
were selected from a publicly available dataset rather than
specifically for the purpose of this study. However, this did
include SNPs and biomarkers relevant to the pathways we
set out to investigate.
The strength of our study is the adequate sample size.
The effective sample size required to test whether a gene
main effect is associated with a continuous trait for 99 %
power, a = 0.05 (two-sided test), assuming outcomes that
are modelled using linear regression (mean 0.52, SD 0.83,
genetic effect = 0.01, MAF = 0.05) is 1828, which is
given in our study. Despite this, it would advantageous to
replicate our findings. Another advantage is the use of
biomarker levels as endophenotypes, which offers addi-
tional biological plausibility for our findings.
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In conclusion, our study provides evidence for the
involvement of the TNF in the pathophysiology of frailty in
line with previous observations in the literature. We also
report new observations of the involvement of a protein
tyrosine phosphatase (PTPRJ), Ataxia Telangiectasia
Mutated (ATM) and Catechol-O-methyltransferase (COMT)
in the frailty phenotype. Although we use biomarker
endophenotypes to support plausibility of these genetic
associations, replication in other cohorts is encouraged.
Nevertheless, these findings provide opportunities to better
understand the biological processes underpinning frailty,
which may over time lead to possible interventions.
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